BR112018010494A8 - proteínas de fusão fmdv e e2 e seus usos - Google Patents

proteínas de fusão fmdv e e2 e seus usos

Info

Publication number
BR112018010494A8
BR112018010494A8 BR112018010494A BR112018010494A BR112018010494A8 BR 112018010494 A8 BR112018010494 A8 BR 112018010494A8 BR 112018010494 A BR112018010494 A BR 112018010494A BR 112018010494 A BR112018010494 A BR 112018010494A BR 112018010494 A8 BR112018010494 A8 BR 112018010494A8
Authority
BR
Brazil
Prior art keywords
fmdv
vaccine
fusion proteins
encompasses
antigens
Prior art date
Application number
BR112018010494A
Other languages
English (en)
Other versions
BR112018010494A2 (pt
Inventor
Sigoillot-Claude Cecile
Reynard Frederic
Audonnet Jean-Christophe
Bomchil Natalia
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of BR112018010494A2 publication Critical patent/BR112018010494A2/pt
Publication of BR112018010494A8 publication Critical patent/BR112018010494A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção abrange vacinas ou composições de fmdv. a vacina ou composição pode ser uma vacina ou composição contendo antígenos de fmdv. a invenção também engloba vetores recombinantes que codificam e expressam antígenos, epítopos ou imunógenos de fmdv que podem ser utilizados para proteger animais, em particular, ovinos, bovinos, caprinos ou suínos contra o fmdv. a invenção abrange ainda métodos de fabricação ou produção de polipeptídeos antigênicos ou antígenos.
BR112018010494A 2015-11-23 2016-11-16 proteínas de fusão fmdv e e2 e seus usos BR112018010494A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23
PCT/US2016/062367 WO2017091418A1 (en) 2015-11-23 2016-11-16 Fmdv and e2 fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
BR112018010494A2 BR112018010494A2 (pt) 2018-11-13
BR112018010494A8 true BR112018010494A8 (pt) 2019-02-26

Family

ID=57570585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010494A BR112018010494A8 (pt) 2015-11-23 2016-11-16 proteínas de fusão fmdv e e2 e seus usos

Country Status (20)

Country Link
US (2) US9913891B2 (pt)
EP (2) EP3539566A1 (pt)
JP (2) JP6797206B2 (pt)
KR (1) KR102153303B1 (pt)
CN (1) CN108367067B (pt)
AR (1) AR106792A1 (pt)
AU (1) AU2016361305B2 (pt)
BR (1) BR112018010494A8 (pt)
CA (1) CA3006078A1 (pt)
DK (1) DK3380119T3 (pt)
ES (1) ES2899230T3 (pt)
HK (1) HK1258695A1 (pt)
MA (3) MA43310A (pt)
MX (1) MX2018006347A (pt)
NZ (1) NZ743236A (pt)
RU (1) RU2714428C2 (pt)
TW (1) TWI744260B (pt)
UY (1) UY36995A (pt)
WO (1) WO2017091418A1 (pt)
ZA (1) ZA201803390B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019179345A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim (China) Investment Co., Ltd. Recombinant virus capable of stably expressing target proteins
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
KR102672787B1 (ko) * 2019-06-28 2024-06-05 (주)플럼라인생명과학 구제역 바이러스 백신 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
WO2006073431A2 (en) 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP2316480A1 (en) * 2006-03-17 2011-05-04 Indian Immunologicals Ltd Chimeric tymovirus-like particles
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
PL2475384T3 (pl) 2009-09-10 2017-02-28 Merial, Inc. Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
CA2792117C (en) 2010-03-12 2016-09-20 Merial Limited Foot and mouth disease virus recombinant vaccines and uses thereof
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
BR112015013135A2 (pt) * 2012-12-05 2017-09-26 Thevax Genetics Vaccine Co Ltd proteínas de fusão para uso como potencializadores imunogênicos para induzir respostas de células t antígeno específicas
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
EP3906939A1 (en) * 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
CN107073100B (zh) 2014-09-23 2021-02-26 勃林格殷格翰动物保健美国公司 Fmdv重组疫苗及其用途

Also Published As

Publication number Publication date
JP2020203890A (ja) 2020-12-24
RU2018122755A (ru) 2019-12-26
KR20180084995A (ko) 2018-07-25
AU2016361305B2 (en) 2020-02-06
US20180169216A1 (en) 2018-06-21
MA42640A1 (fr) 2019-05-31
EP3539566A1 (en) 2019-09-18
BR112018010494A2 (pt) 2018-11-13
DK3380119T3 (da) 2021-11-15
UY36995A (es) 2017-06-30
MA49414A (fr) 2020-04-22
CA3006078A1 (en) 2017-06-01
NZ743236A (en) 2019-12-20
CN108367067B (zh) 2022-05-03
TWI744260B (zh) 2021-11-01
MX2018006347A (es) 2019-02-20
US10363300B2 (en) 2019-07-30
AR106792A1 (es) 2018-02-21
ZA201803390B (en) 2019-03-27
WO2017091418A1 (en) 2017-06-01
RU2714428C2 (ru) 2020-02-14
US20170143819A1 (en) 2017-05-25
EP3380119A1 (en) 2018-10-03
MA43310A (fr) 2021-04-28
JP6797206B2 (ja) 2020-12-09
RU2018122755A3 (pt) 2019-12-26
HK1258695A1 (zh) 2019-11-15
EP3380119B1 (en) 2021-08-25
US9913891B2 (en) 2018-03-13
AU2016361305A1 (en) 2018-06-28
TW201726708A (zh) 2017-08-01
MA42640B1 (fr) 2021-06-30
KR102153303B1 (ko) 2020-09-09
JP2019500409A (ja) 2019-01-10
CN108367067A (zh) 2018-08-03
ES2899230T3 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
BR112017005833A2 (pt) vacinas recombinantes fmdv e seus usos
BR112018010494A2 (pt) proteínas de fusão fmdv e e2 e seus usos
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
BR112018015345A8 (pt) Vacinas fmdv vetoriadas de adenovírus recombinante e suas utilizações
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
NZ725212A (en) Group a streptococcus vaccine
BR112017027895A2 (pt) vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
CO2018001985A2 (es) Polipéptidos mrka, anticuerpos y usos de los mismos
NZ734938A (en) Leptospira immunoprotective proteins and methods of identification and use thereof
UY36328A (es) Vacunas de fmdv recombinante y usos de las mismas
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof
NZ629420A (en) Sheep nematode vaccine
CL2013002782A1 (es) Formulación inmunogénica para inducir la respuesta inmune en un sujeto que comprende una mezcla de bacterias no patógenas que expresan cada una un segmento hipervariable de la proteína m de diferentes streptococcus pyogenes; uso de la formulación para producir una vacuna; método para producir vacuna
BR112013002199A2 (pt) parasita trypanosoma theileri recombinante
AR095501A1 (es) Vacunas rsv

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: MERIAL, INC. (US)

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]